The Emergence of Oral Sildenafil for Pulmonary Hypertension Management

4 August 2025

Ghazwan Butrous

https://doi.org/10.1002/pul2.70150

Abstract

The letter detailed a patient suffering from severe primary pulmonary hypertension (PPH) who had deteriorated to the point of being unable to walk even 100 m. Traditional treatments, such as epoprostenol infusion or transplantation, were rejected by the patient at that time. With limited options, Dr. Gatzoulis's team administered sildenafil at a daily maintenance dose of 500 mg (100 mg five times daily). This decision was based on observational reports of its use as a nitric oxide enhancer in children from London and Boston. The patient tolerated the treatment well and made significant improvements.

Read the full historical vignette

Share: